FocalTherics prices public offering of 8.4 million ADS at $4.75 each

FocalTherics (NASDAQ: FOCL) has priced an underwritten public offering of 8,425,000 American Depositary Shares (ADSs) at $4.75 per ADS, according to a press release from the company.

Each ADS represents one ordinary share of the company, with a nominal value of €0.13 per share. All ADSs are being sold by the company. The gross proceeds from the offering are expected to be approximately $40.0 million before underwriting discounts, commissions, and other expenses.

The underwriters have been granted a 30-day option to purchase up to an additional 1,263,750 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on Aug. 14, 2026, subject to customary closing conditions.

TD Cowen and Mizuho are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Lucid Capital Markets are serving as co-managers.

The offering is being made pursuant to a shelf registration statement on Form S-3, previously filed with the Securities and Exchange Commission on March 25, 2026, and declared effective on March 31, 2026. No public offering of the ADSs will be made in Europe.

FocalTherics, headquartered in Austin, Texas, with operations in Lyon, France, develops and markets medical devices using focused ultrasound technology.

You May Also Be Interested In

• Yarrow Bioscience prices $150M public offering at $26 per share
• Copart to buy ACV for $1.9 billion in cash deal
• Thomson Reuters prices $1.3B U.S. notes and C$1B Canadian notes